{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:16:04Z","timestamp":1783577764093,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Flexitrate, an innovative regional citrate anticoagulation (RCA) protocol, was compared to traditional RCA (tRCA) and Heparin anticoagulation protocols in intensive care patients treated with continuous renal replacement therapy (CRRT).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A single-center, retrospective, cohort study, was done in a 26-bed intensive care unit in a large community hospital. Eighty dialysis sessions (Flexitrate\u2009=\u20092852\u2009h, tRCA\u2009=\u20093580\u2009h and Heparin\u2009=\u20092026\u2009h), performed in 53 patients, were evaluated for filter life, RCA control, and metabolic control.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the Flexitrate cohort, 3.8% of filters clotted, compared to 16.9% with tRCA and 28.3% with Heparin (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.001 for Flexitrate compared to either tRCA or Heparin). Filter survival was significantly improved with Flexitrate compared to tRCA (HR 0.24, <jats:italic>p<\/jats:italic>\u00a0=\u20090.018) or Heparin (HR 0.14, <jats:italic>p<\/jats:italic>\u00a0=\u20090.004).<\/jats:p>\n<jats:p>Anticoagulation control was superior with Flexitrate with Patient Ionized Calcium out of target a median of 16% of the time, compared to 27% for tRCA (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.001). Filter Ionized Calcium was out of target a median of 6.8% of the time, compared to 23% for tRCA (<jats:italic>p<\/jats:italic>\u00a0=\u20090.03).<\/jats:p>\n<jats:p>Flexitrate produced significantly less alkalosis, hypernatremia, and hypocalcemia than tRCA, and overall metabolic control was comparable to Heparin anticoagulation. The only adverse metabolic outcome with Flexitrate was increased hypomagnesemia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The Flexitrate protocol extended filter life, delivered more consistent anticoagulation, and provided superior metabolic control compared to a tRCA protocol. Filter life was superior to Heparin anticoagulation, with similar metabolic control. A randomized control trial comparing these protocols is recommended.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-019-1648-8","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T16:02:52Z","timestamp":1575561772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Flexitrate regional citrate anticoagulation in continuous venovenous hemodiafiltration: a retrospective analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8417-4128","authenticated-orcid":false,"given":"Ilan","family":"Lenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma M.","family":"Hopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Hume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C. Y.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"issue":"9","key":"1648_CR1","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3109\/0886022X.2015.1074490","volume":"37","author":"C Thongprayoon","year":"2017","unstructured":"Thongprayoon C, Cheungpasitporn W, Ahmed AH. Trends in the use of renal replacement therapy modality in intensive care unit: a 7 year study. Ren Fail. 2017;37(9):1444\u20137.","journal-title":"Ren Fail"},{"key":"1648_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/ki.1990.300","volume":"38","author":"RL Mehta","year":"1990","unstructured":"Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in crucially ill patients. Kidney Int. 1990;38:976\u201381.","journal-title":"Kidney Int"},{"key":"1648_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00134-011-2438-3","volume":"38","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing Continous renal replacement therapy. Intensive Care Med. 2012;38:20\u20138.","journal-title":"Intensive Care Med"},{"key":"1648_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000245648","volume":"29","author":"B Szamosfalvi","year":"2010","unstructured":"Szamosfalvi B, Frinak S, Yee J. Automated regional citrate anticoagulation: technological barriers and possible solutions. Blood Purif. 2010;29:204\u20139.","journal-title":"Blood Purif"},{"key":"1648_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1046\/j.1523-1755.2001.00809.x","volume":"60","author":"A Tolwani","year":"2001","unstructured":"Tolwani A, Campbell R, Schenk M, Allon M, Warnock DC. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int. 2001;60:370\u20134.","journal-title":"Kidney Int"},{"issue":"2","key":"1648_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1525-139X.2008.00550.x","volume":"22","author":"KW Finkel","year":"2009","unstructured":"Finkel KW, Podoll AS. Complications of continuous renal replacement therapy. Semin Dialysis. 2009;22(2):155\u20139.","journal-title":"Semin Dialysis"},{"issue":"10","key":"1648_CR7","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00134-002-1443-y","volume":"28","author":"L Gabutti","year":"2002","unstructured":"Gabutti L, Marone C, Colucci G, Duchini F, Schonholzer C. Citrate anti-coagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med. 2002;28(10):1419\u201325.","journal-title":"Intensive Care Med"},{"key":"1648_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2215\/CJN.00040505","volume":"1","author":"AJ Tolwani","year":"2006","unstructured":"Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation Continous Venovenous Hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol. 2006;1:79\u201397.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1648_CR9","first-page":"131","volume":"16","author":"MJ Brain","year":"2014","unstructured":"Brain MJ, Roodenburg OS, Adams N, McCracken P, Hockings L, Musgrave S, et al. Randomised trial of software algorithm-driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the filter life in renal replacement therapy pilot trial. Crit Care Resusc. 2014;16:131\u20137.","journal-title":"Crit Care Resusc"},{"key":"1648_CR10","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2215\/CJN.01280214","volume":"9","author":"S Morabito","year":"2014","unstructured":"Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol. 2014;9:2173\u201388.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1648_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00134-003-2047-x","volume":"30","author":"M Monchi","year":"2004","unstructured":"Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260\u20135.","journal-title":"Intensive Care Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1648-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1648-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1648-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:14:16Z","timestamp":1607040856000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1648-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1648"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1648-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was reviewed and approved by the Research Ethics Board of Lakeridge Health Hospital, and the need for informed consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The lead author (IL) received payments from Baxter Corporation for preparing promotional materials and for speaking engagements on the same topic. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}